Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021
Today, on 21 May 2021, the annual general meeting was held in SynAct Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
Resolution on adoption of accounts and allocation of the company’s result Uppdaterad 2021-05-21 Publicerad 2021-05-21
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the board of directors to allocate the company s result, meaning that no dividends are paid a
Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
AcelRx Pharmaceuticals Reports - GuruFocus com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
The Group s profit before tax amounted to -14,070 ( -3,822) TSEK.
The Group s earnings per share amounted to -0.46 (-0.14).
The average number of shares for the period was 25,366,295. SynAct Pharma AB means the parent company SynAct Pharma AB with corporate registration number 559058-4826. The Company or SynAct means the Group, i.e. SynAct Pharma AB and its wholly owned subsidiary SynAct Pharma ApS.
definitions
Earnings per share: Profit for the period divided by the average number of shares outstanding in the period.
Equity/assets ratio: Equity divided by total capital.
Significant events in Q1 2021
On January 11, board member and CSO Thomas Jonassen and CEO Jeppe Øvlesen carried out a restructuring in which the respective holdings of shares in SynAct have transferred to the newly formed company BioInvest ApS.
SynAct Pharma shareholders propose Marina Bozilenko as new board member
SynAct Pharma AB ( SynAct ) today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct Pharma at the next annual general meeting set for May 21, 2021. Uppdaterad 2021-04-19 Publicerad 2021-04-19
Marina Bozilenko has more than 30 years of experience in investment banking and the healthcare industry, including raising more than $30 billion in capital and executing numerous M&A transactions.
Ms. Bozilenko currently serves as Strategic Advisor to William Blair & Company, a firm she joined in 2010 as Head of Biotech & Pharma and Managing Director. Prior to that, she worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group, at Bank of America Securities as a managing director and head of biotechnology, and at Ve